NeoChord lands CE Mark for its mitral valve repair system

January 4, 2013 by MassDevice staff

Minnesota-based medical device maker NeoChord  receives CE Mark approval to market its DS1000 Mitral Valve Repair Device in European Union.

NeoChord logo

Minnesota device maker NeoChord won CE Mark approval in the European Union for its DS1000 Mitral Valve Repair system, the company announced this week.

The device allows the implantation of artificial chordae tendinae, thread-like tissues that anchor the leaflets of the mitral valve to heart muscle. Surgeons can use the device to repair mitral valve prolapse via a transapical, off-pump procedure, according to the company.

Sign up to get our free newsletters delivered right to your inbox.

The company also announced the start of its 50-patient Transapical Artificial Chordae Tendinae registry, with the initial commercial procedure expected in Q1 2013.

"Receiving CE marking for the NeoChord device ... and beginning the TACT Registry are meaningful steps forward in the treatment of patients with severe mitral regurgitation," NeoChord primary inventor Dr. Giovanni Speziali said in prepared remarks. "The NeoChord procedure allows patients an alternative to still undergo a quality repair without enduring the rigors of traditional treatment via open-chest surgery performed on a stopped heart."

The Minnesota-based NeoChord in January 2011 raised $1 million to tide it over, adding to it a $11 million round which was nearly half completed by August 2011.